Clinical trials: Resistance, Disease
Diabetes Mellitus, Type 2, Skeletal Muscle Insulin Sensitivity
Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.
The purpose of this study is to investigate the effects of 5 weeks treatment with dapagliflozin in type 2 diabetes patients on how the hormone insulin acts on sugar uptake in muscles.
- Trial name
- DAPAMAAST (NCT03338855)
- Testing
- Dapagliflozin
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
Metabolic Syndrome
Metabolic Syndrome Feasibility Study
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with…
- Trial name
- EPIC-009 (NCT02287766)
- Where
- 2 sites in United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Treatment Resistant Depression
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
This is a double-blind, randomized, placebo-controlled, multicenter study comprised of 3 phases:screening (up to 2 weeks [Day -15 to Day -2]), In-Clinic Treatment (Day -1 to Day 2; including double-blind treatment [Day 1]), and…
- Trial name
- NCT05414422
- Testing
- PCN-101
- Where
- 21 sites in United States, Germany and 1 more
- Volunteers
- 102 people
- Sponsor
- Perception Neuroscience
Depressive Disorder, Treatment-Resistant
An Epidemiology Study of Treatment Resistant Depression in the United States (US)
The purpose of this study is to describe the epidemiology of Treatment Resistant Depression (TRD) in the US, including the population incidence of TRD, and TRD as a proportion of Pharmacologically Treated Depression (PTD), and…
- Trial name
- NCT03109002
- Volunteers
- 200,000 people
- Sponsor
- Janssen Research & Development, LLC
Metabolic Syndrome, Dyslipidemia
Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)
The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.
- Trial name
- NCT00240266
- Testing
- Rosuvastatin
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Prehypertension, Elevated Blood Pressure
Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
This clinical study aims to assess the efficacy of TOTUM-854, a mix of 6 plant extracts, consumed twice a day on automated office blood pressure in subjects with moderately elevated blood pressure.
- Conditions
- Prehypertension, Elevated Blood Pressure, Blood Pressure, Metabolic Syndrome
- Trial name
- INSIGHT (NCT05469503)
- Testing
- TOTUM-854
- Where
- 10 sites in Bulgaria, France and 1 more
- Volunteers
- 410 people
- Sponsor
- Valbiotis
Shingles
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).
- Trial name
- NCT00109122
- Testing
- zoster vaccine live (Oka/Merck)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386.
- Trial name
- EPI-7386 (NCT04421222)
- Testing
- EPI-7386 (QD), EPI-7386 (BID), Abiraterone acetate
- Where
- 9 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- ESSA Pharmaceuticals
Treatment Resistant Depression, Major Depressive Disorder
Mechanistic Evaluation of Response in TRD (MERIT)
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in…
- Trial name
- MERIT (NCT04608396)
- Testing
- AXS-05
- Where
- 20 sites in United States
- Volunteers
- 44 people
- Sponsor
- Axsome Therapeutics, Inc.
Hypertension, High Blood Pressure
A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension
To evaluate the safety and effectiveness of the ROX Coupler used to create an arteriovenous anastomosis in the iliac region (between the iliac artery and vein) in subjects with hypertension.
- Trial name
- CONTROL HTN-2 (NCT02895386)
- Testing
- ROX Coupler
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- ROX Medical, Inc.
Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
The purpose of this study is to determine whether nalfurafine hydrochloride is effective and safe in the treatment for conventional-treatment-resistant pruritus in patients receiving hemodialysis.
- Trial name
- TRK-820 (NCT01513161)
- Testing
- nalfurafine hydrochloride (TRK-820)
- Where
- South Korea
- Volunteers
- 104 people
- Sponsor
- SK Chemicals Co., Ltd.
Tuberous Sclerosis Complex, Epilepsy
Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC).
- Trial name
- RESTOR-1 (NCT07680322)
- Testing
- AV078
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Aeovian Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2
Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects
The objective of this early feasibility study is to evaluate the safety and performance of intravascular hepatic denervation using the Metavention Integrated Radio Frequency Denervation System (iRF System) to improve glycemic…
- Trial name
- DeLIVER (NCT04285554)
- Testing
- iRF System Hepatic Denervation
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Metavention
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Chronic Lymphocytic Leukemia
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
The study is a Phase 1b open label, non-randomized, single institution clinical trial that is designed to evaluate the safety and tolerability of three repeat infusions of ISF35 followed by a standard regimen of three cycles of…
- Trial name
- NCT00772486
- Testing
- ISF35
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Memgen, LLC
Methicillin Resistant Staphylococcus Aureus (MRSA)
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects.
- Trial name
- ZEPHYR (NCT00084266)
- Testing
- linezolid (Zyvox), vancomycin
- Where
- 177 sites in United States, Argentina and 20 more
- Volunteers
- 1,225 people
- Sponsor
- Pfizer
Lennox-Gastaut Syndrome
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
This Phase 3 trial will enroll participants diagnosed with Lennox-Gastaut Syndrome (LGS) who are still experiencing at least 4 motor seizures involving the trunk or extremities per week, despite ongoing treatment with up to 3…
- Trial name
- NCT02318537
- Testing
- Cannabidiol Oral Solution
- Sponsor
- INSYS Therapeutics Inc
Gastrointestinal Stromal Tumors (GIST)
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
The mainstay of therapy for GISTs is surgical resection, however, recurrence is almost inevitable in high-risk tumors and secondary surgery or other salvage therapy has yielded poor outcome.
- Trial name
- NCT00633295
- Testing
- AMN107- NILOTINIB
- Where
- 3 sites in Israel
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Myeloid Leukemia, Chronic, Chronic Phase
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI)…
- Trial name
- OPTIC (NCT02467270)
- Testing
- Ponatinib
- Where
- 86 sites in United States, Argentina and 19 more
- Volunteers
- 283 people
- Sponsor
- Takeda
Prostate Cancer
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after…
- Trial name
- PSMAcTION (NCT06780670)
- Testing
- Investigators choice of SoC, AAA817
- Where
- 93 sites in United States, Australia and 11 more
- Volunteers
- 443 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.